Table 3.
Poliovirus Neutralizing Antibody Geometric Mean Titers (GMTs) at Baseline and After Receipt of Inactivated Polio Vaccine (IPV) Booster
| Group, IPV Formulation | Serotype 1, GMT (95% CI) |
Serotype 2, GMT (95% CI) |
Serotype 3, GMT (95% CI) |
|||
|---|---|---|---|---|---|---|
| Baseline | After Booster | Baseline | After Booster | Baseline | After Booster | |
| Group 1, 40% ID | 44 (31–64) | 1715 (1174–2504) | 33 (24–44) | 2188 (1507–3178) | 14 (10–20) | 2375 (1423–3963) |
| Group 2, 20% ID | 42 (29–59) | 976 (730–1304) | 53 (37–76) | 1438 (984–2101) | 20 (14–28) | 1698 (1114–2588) |
| Group 3, 100% IM | 42 (30–58) | 1249 (916–1705) | 36 (26–51) | 1489 (1041–2128) | 16 (11–21) | 1792 (1133–2835) |
| Group 4, 40% IM | 34 (20–56) | 1328 (795–2219) | 44 (29–66) | 1938 (1232–3047) | 11 (7–16) | 2075 (1225–3514) |
There were data on baseline GMT for 66, 66, 66, and 33 subjects and on postbooster GMT for 65, 63, 64, and 32 subjects for groups 1, 2, 3, and 4, respectively. There were no significant differences between study groups for either baseline or postbooster GMTs.
Abbreviations: CI, confidence interval; ID, intradermal; IM, intramuscular.